placebo + insulin icodec

This is a combination of placebo and insulin icodec, typically used in clinical trials as a control or comparator arm. Insulin icodec is an ultra-long-acting basal insulin analogue designed for once-weekly subcutaneous injection to improve glycemic control in adults with diabetes mellitus. It works by binding to the human insulin receptor, stimulating peripheral glucose uptake (especially by skeletal muscle and fat), inhibiting hepatic glucose production, suppressing lipolysis and proteolysis, and enhancing protein synthesis. The molecular modifications of insulin icodec—such as amino acid substitutions and addition of a C20 fatty diacid side chain—increase albumin binding and extend its half-life to approximately eight days[1][2][4][5][7]. Placebo has no pharmacological activity but is included for blinding or comparison purposes in clinical studies.